The recall only affects the sensor component of the FreeStyle Libre 3 system, which also includes a reader and an app.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

The key differences between Dexcom and FreeStyle Libre include sensor characteristics, frequency of readings, minimum age of ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom's prescription-free Stelo follows the popular G6 and G7 CGM technology for people who ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

The FreeStyle Libre 3 sensor is a component of Abbott’s popular FreeStyle Libre 3 continuous glucose monitoring system (CGM). Abott’s FreeStyle Libre range generated $1.4bn in sales in Q4 2023 ...

Pharmacies have been turning patients away as deliveries of healthcare firm Abbott's Freestyle Libre Sensor are delayed by two or three weeks. Abbott has said it is working hard to fulfil all the ...

[Harley] decided not to wait and managed to interface an Abbot FreeStyle Libre sensor with the Apple watch. The sensor doesn’t directly read glucose continuously, but it does allow for more ...

[Harley] decided not to wait and managed to interface an Abbot FreeStyle Libre sensor with the Apple watch. The sensor doesn’t directly read glucose continuously, but it does allow for more ...

DexCom (NASDAQ: DXCM) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

The planned launch of Omnipod 5 with Abbott’s Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock.